Advertisement

Topics

Biogen Gets EU Panel OK for MS Drug

10:23 EDT 20 May 2011 |

Weston, MA-based Biogen Idec (NASDAQ: BIIB) said today that it has received a positive opinion from a committee of the European Medicines Agency, which should pave the way to begin sales in Europe of fampridine (Fampyra) as a new treatment for multiple sclerosis. Based on the committee recommendation, Biogen Idec said it expects to be [...]

Original Article: Biogen Gets EU Panel OK for MS Drug

NEXT ARTICLE

More From BioPortfolio on "Biogen Gets EU Panel OK for MS Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...